Annual medication readjustment: increase will be up to 4.33%

It is usually done taking into account some factors that may have an impact on the value, such as inflation in the last 12 months, the production of medicines in industries, the exchange rate and the electricity tariff.

And they are valid for those drugs that need a prescription to be sold.

In addition, some groups of drugs have different adjustment ceilings – but all within this range of, at most, 4.33%.

This is because the different outlets in the market are taken into account, be it high, moderate or low competition. That is, the more companies or brands manufacturing, the greater the competition.

Medicines like omeprazole and pantoprazole are part of the high competition group, as there are several brands, including generics, available. These can have the maximum readjustment of up to 4.33%.

Since ketoconazole and tramadol , which are antifungal and participate in the competition moderate group have a slightly smaller increase compared to the first.

Those with low competition, or concentrated competition, such as betamethasone and dexamethasone , have the lowest adjustment in the category.

According to the Ministry of Health, companies that do not comply with prices within the adjustment, or increase the percentage more than the established, can pay a fine of up to 9.7 million.